FTC Receives More than 20,000 Responses to its Request for Comments on PBM Practices


Providers want the Federal Trade Commission (FTC) to investigate pharmacy benefit managers’ (PBM) business practices. The FTC published a notice in February asking for input on how PBM practices such as rebates and fees, potentially anti-competitive contracts, and attempts to steer patients toward certain pharmacies affect patients and payers. The commission received more than 23,700 submissions by the time the comment period expired Wednesday. Providers wrote that PBMs engage in practices that decrease the quality and threaten providers’ finances.